The Evidentic Blog

Explore expert articles, industry trends, and practical tips to support your early-stage drug development.

AllBispecific antibodiesAnalyticsUncategorizedBiosimilarsTherapeutic mAbsScientific Resources

Advancing ADC Development Programs: How Clinical Grade Reference Drugs Can Add Value

Establishing Critical Quality Attributes (CQAs) in Biologics: How Clinical-Grade Reference Drugs Inform CQA Identification and Risk Assessment

Understanding Endotoxin Levels in Biologics: Regulatory Trends and the Role of Reference Drugs

Why Choosing the Right Functional mAb Matters: The Advantage of Clinical-Grade Reference Molecules

Clinical vs Research-Grade Reference Molecules: Strengthening Academic Biologics Research

Therapeutic Monoclonal Antibody Characterization: Using Clinical-Grade Reference Drugs to Enhance Early Development

Early Phase Biologics Development: The Pipeline (Part 1)

Solubility of ADCs: Influencing Factors and Optimization Tips

Biological Orphan Drugs: Key Definitions and Regulations

Therapeutic Antibodies: The Different Formats

Early Phase Biologics Development: Lead Generation and Optimization (Part 3)

Early Phase Biologics Development: Target Research (Part 2)

The Development of Anti-Drug Antibody (ADA) – Based Assays

Cell Therapy Using Chimeric Antigen Receptors (CARs)

Using Antibody Drug Conjugates (ADC) for Therapy

Bispecific Antibodies: The Next Generation of Antibody Therapeutics (Part 2)

Therapeutic Antibodies to Treat Cancer Targeting CD20

Reference Drugs (RMPs/RLDs) and Reference Standards: Exploring the Difference

Monoclonal Antibody Therapy

The Advent of Therapeutic Antibodies

Biosimilar Development: A Biocomparability Exercise

Anti-IL-6R mABs for Rheumatoid Arthritis

Biologic Drugs for Rheumatoid Arthritis

Exploring the Certificate of Analysis (CoA)